S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NYSE:ADCT

ADC Therapeutics News Headlines

$16.78
-0.16 (-0.94%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.42
$17.43
50-Day Range
$16.78
$27.88
52-Week Range
$16.35
$34.48
Volume
216,804 shs
Average Volume
189,700 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.2
Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

ADC Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADCT
News Sentiment

-0.03

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADCT Articles
This Week

9

1

ADCT Articles
Average Week



ADC Therapeutics (NYSE:ADCT) News Headlines Today

SourceHeadline
finance.yahoo.com logoADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan
finance.yahoo.com - January 18 at 1:04 PM
seekingalpha.com logoADC Therapeutics inks exclusive license with MTPC to develop and commercialize ZYNLONTA in Japan
seekingalpha.com - January 18 at 8:04 AM
finance.yahoo.com logoADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
finance.yahoo.com - January 18 at 8:04 AM
MarketBeat logoADC Therapeutics (NYSE:ADCT) Reaches New 1-Year Low at $18.31
americanbankingnews.com - January 14 at 11:30 AM
MarketBeat logoADC Therapeutics (NYSE:ADCT) Trading Up 4%
americanbankingnews.com - January 13 at 2:36 PM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
finanznachrichten.de - December 28 at 8:15 PM
nasdaq.com logoADC Therapeutics Becomes Oversold (ADCT)
nasdaq.com - December 14 at 12:53 PM
finance.yahoo.com logoAre Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 50%?
finance.yahoo.com - November 4 at 10:36 AM
finance.yahoo.com logoADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
finance.yahoo.com - November 4 at 10:36 AM
fool.com logoADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
fool.com - November 3 at 3:20 AM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 2 at 1:18 PM
finance.yahoo.com logoADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - November 2 at 8:18 AM
finance.yahoo.com logoADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
finance.yahoo.com - October 29 at 10:01 AM
finance.yahoo.com logoADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
finance.yahoo.com - October 27 at 9:35 AM
marketwatch.com logoADC Therapeutics Doses First Patient in Phase 1 Cancer Trial
marketwatch.com - September 27 at 2:48 PM
finance.yahoo.com logoADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
finance.yahoo.com - September 27 at 9:47 AM
finance.yahoo.com logoADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 23 at 8:38 AM
finance.yahoo.com logoADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
finance.yahoo.com - September 13 at 9:40 AM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference
finanznachrichten.de - September 10 at 10:49 PM
finance.yahoo.com logoADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
finance.yahoo.com - September 9 at 8:58 AM
nasdaq.com logoADCT Crosses Below Key Moving Average Level
nasdaq.com - September 8 at 10:58 PM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics Announces Medical Leadership Transition
finanznachrichten.de - September 3 at 1:28 PM
nasdaq.com logoADC Therapeutics Names Joseph Camardo Chief Medical Officer - Quick Facts
nasdaq.com - September 3 at 1:28 PM
finance.yahoo.com logoADC Therapeutics Announces Medical Leadership Transition
finance.yahoo.com - September 3 at 1:28 PM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
finanznachrichten.de - August 27 at 1:36 AM
finance.yahoo.com logoADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
finance.yahoo.com - August 26 at 3:32 PM
finance.yahoo.com logoADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
finance.yahoo.com - August 26 at 3:32 PM
nasdaq.com logoADC Therapeutics Breaks Above 200-Day Moving Average - Bullish for ADCT
nasdaq.com - August 9 at 2:42 PM
finance.yahoo.com logoIs ADC Therapeutics (NYSE:ADCT) Using Debt In A Risky Way?
finance.yahoo.com - August 6 at 10:44 AM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 3 at 5:40 PM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 3 at 12:40 PM
seekingalpha.com logoADC Therapeutics SA 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 3 at 12:31 PM
finance.yahoo.com logoADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - August 3 at 7:32 AM
finance.yahoo.com logoADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
finance.yahoo.com - July 28 at 6:20 PM
businesswire.com logoADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16 th Annual International ...
businesswire.com - June 22 at 2:51 PM
finance.yahoo.com logoADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
finance.yahoo.com - June 18 at 7:27 AM
finance.yahoo.com logoADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
finance.yahoo.com - June 11 at 11:41 AM
finance.yahoo.com logoADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
finance.yahoo.com - June 9 at 10:02 AM
finance.yahoo.com logoADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
finance.yahoo.com - June 4 at 5:43 PM
finance.yahoo.com logoADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 9:37 AM
finance.yahoo.com logoADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
finance.yahoo.com - May 26 at 7:58 AM
finance.yahoo.com logoAvid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
finance.yahoo.com - May 25 at 8:31 AM
finance.yahoo.com logoADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
finance.yahoo.com - May 19 at 11:16 PM
finance.yahoo.com logoADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
finance.yahoo.com - May 17 at 9:11 AM
finance.yahoo.com logoADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
finance.yahoo.com - May 12 at 8:40 AM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 12:38 AM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
finanznachrichten.de - May 6 at 2:37 PM
nasdaq.com logoADC Therapeutics Q1 Net Loss Widens
nasdaq.com - May 6 at 2:37 PM
finance.yahoo.com logoADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - May 6 at 2:37 PM
benzinga.com logoADC Therapeutics' ZYNLONTA™ (loncastuximab...
benzinga.com - May 5 at 9:07 PM
Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.